Major Depressive Disorder Clinical Trials in New York, New York

24 studies are recruiting for major depressive disorder in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

   X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Fieve Clinical Research, Inc., New York, New York

   Locations

   50 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT07076407 on ClinicalTrials.gov

2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

   This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Manhattan Behavioral Medicine, New York, New York

   Locations

   69 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT05850689 on ClinicalTrials.gov

3. NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, New York, New York

   Locations

   39 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06911112 on ClinicalTrials.gov

4. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, New York, New York

   Locations

   35 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06963021 on ClinicalTrials.gov

5. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Adams Clinical Harlem, New York, New York

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

6. A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   IMA Clinical Research - NYC Midtown, New York, New York

   Locations

   32 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT07115329 on ClinicalTrials.gov

7. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, New York, New York

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

8. Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)

   This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minu…

   Stage

   Not phased

   Ages

   24 to 65

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07111390 on ClinicalTrials.gov

9. DBS for TRD With the Medtronic Percept PC

   Of the estimated 30 million Americans who suffer from Major Depressive Disorder, approximately 10% are considered treatment resistant. Deep brain stimulation (DBS) to a region of the brain called the subcallosal cingulate (SCC) is an emerging strategy for treatment resistant depression (TRD), which…

   Stage

   Not phased

   Ages

   25 to 70

   Site

   Icahn School of Medicine at Mount Sinai, Mount Sinai West, New York, New York

   Run by

   Helen Mayberg, MD

   See if you can join NCT05773755 on ClinicalTrials.gov

10. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, ti…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Ima Clinical Research - Manhattan /ID# 278212, New York, New York

    Locations

    33 in total

    Run by

    AbbVie

    See if you can join NCT07276997 on ClinicalTrials.gov

11. tDCS: Sleep to Mood in Depression (S2M-D)

    The purpose of this study is to determine whether changes in sleep consolidation occur during home-based transcranial direct current stimulation (tDCS) in adults with moderate depression and whether these changes are temporally associated with improvements in depressive symptoms.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT07572526 on ClinicalTrials.gov

12. Triage Survey for Psychiatry Research Eligibility

    TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Adams Clinical, Harlem, New York, New York

    Locations

    6 in total

    Run by

    Adams Clinical

    See if you can join NCT05800925 on ClinicalTrials.gov

13. Aβ Dynamics in LLMD

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and as…

    Stage

    Phase 4

    Ages

    60 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05004987 on ClinicalTrials.gov

14. Maintenance rTMS for Depression (Maitr-De)

    Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Weill Cornell Medicine, New York, New York

    Locations

    3 in total

    Run by

    University of California, San Diego

    See if you can join NCT06938841 on ClinicalTrials.gov

15. Neutralizing Interleukin (IL)-6

    The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major Depressive Disorder (MDD) and evidence of peripheral immune activation. IL-6 is a pro-inflammatory cytokine implicated i…

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT07493317 on ClinicalTrials.gov

16. Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality

    The investigators hypothesized that during the 9-week course of Engage \& Connect treatment there will be an increase in brain functions of the Positive Valence System which in turn will lead to reduction in suicidality.

    Stage

    Not phased

    Ages

    50 to 80

    Site

    Weill Cornell Medicine, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT05925322 on ClinicalTrials.gov

17. Biomarker-guided rTMS for Treatment Resistant Depression

    Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magne…

    Stage

    Phase 3

    Ages

    22 to 65

    Site

    Weill Cornell Medicine, New York, New York

    Locations

    2 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT04041479 on ClinicalTrials.gov

18. Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression - R33

    The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.

    Stage

    Not phased

    Ages

    18 to 65

    Site

    NYU Langone Health, New York, New York

    Locations

    3 in total

    Run by

    NYU Langone Health

    See if you can join NCT05573074 on ClinicalTrials.gov

19. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Autobahn Site #125, New York, New York

    Locations

    50 in total

    Run by

    Autobahn Therapeutics, Inc.

    See if you can join NCT06633016 on ClinicalTrials.gov

20. Invasive Decoding and Stimulation of Altered Reward Computations in Depression Patients

    Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions have shown promise as anatomic…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT05239780 on ClinicalTrials.gov

21. Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

    The proposed study is a single-site, randomized, controlled clinical trial (RCT) comparing ketamine-assisted psychotherapy (KAP) to a standard evidence-based regimen of ketamine administered in a medical model without psychotherapy (KET). Eligible study participants will be adults with major depres…

    Stage

    Phase 2

    Ages

    18 to 90

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06559826 on ClinicalTrials.gov

22. Neural Circuit Effects of Ketamine in Depression

    This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06213324 on ClinicalTrials.gov

23. Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

    This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at sev…

    Stage

    Phase 2

    Ages

    21 to 80

    Site

    Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06592833 on ClinicalTrials.gov

24. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Clinical Research Site, New York, New York

    Locations

    40 in total

    Run by

    Axsome Therapeutics, Inc.

    See if you can join NCT06223880 on ClinicalTrials.gov